Brief: Ampio Pharmaceuticals Announces Patient Randomization And Dosing In AP-019 Phase Ii Study Of Inhaled Ampion In Covid-19 Respiratory Distress
25/06/2021 15:33
June 25 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO PHARMACEUTICALS ANNOUNCES PATIENT RANDOMIZATION AND
DOSING
IN AP-019 PHASE II STUDY OF INHALED AMPION IN COVID-19
RESPIRATORY DISTRESS
Source text for Eikon: ID:nPn6QGW4Ma
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank